摘要
肺癌是癌症死亡的重要原因。驱动基因的发现使肿瘤治疗不再"一刀切"。靶向治疗改变了癌症药物治疗的现状成为"带眼睛的子弹",其疗效可见并为肺癌治疗带来一场革命。驱动基因及靶向治疗已经成为非小细胞肺癌(non-small cell lung cancer,NSCLC)新的代名词。2013年中国美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会发布了关于NSCLC的11种驱动基因突变频率,本文将就此11种NSCLC驱动基因突变的结构、功能及靶向药物治疗进行阐述。
Lung cancer is the leading cause of cancer-related mortality in the worldwide. The discovery of drive gene makes tumor treatment is no longer ＂one-size-fits-all＂. Targeted therapy to change the present situation of cancer drugs become ＂bullet＂ with eyes, the effect is visible and bring a revolution in the treatment of lung cancer. The diver gene and tar- geted therapy have became the new cedule of non-small cell lung cancer （NSCLC）. Society of Clinical Oncology （ASCO） has showed 11 kinds of diver genes. Here, we review the functional and structural characteristics and the targeted therapy in the 11 kinds of driver gene mutations.
出处
《中国肺癌杂志》
CAS
北大核心
2014年第10期750-754,共5页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
驱动基因
靶向治疗
Lung neoplasms
Driver gene
Targeted therapy
